ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SENS Senseonics Holdings Inc

0.435
0.0029 (0.67%)
01 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Senseonics Holdings Inc AMEX:SENS AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.0029 0.67% 0.435 0.4393 0.426 0.4316 929,157 01:00:00

Senseonics Holdings, Inc. to Participate in Upcoming Conferences

02/05/2024 1:05pm

Business Wire


Senseonics (AMEX:SENS)
Historical Stock Chart


From May 2024 to Jun 2024

Click Here for more Senseonics Charts.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference, being held in New York, NY.

Management is scheduled to participate in the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35pm ET and will hold one-on-one meetings.

Management is scheduled to participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 4:00pm ET and will hold one-on-one meetings.

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

Senseonics Investor Contact Philip Taylor Gilmartin Group 415-937-5406 Investors@senseonics.com

1 Year Senseonics Chart

1 Year Senseonics Chart

1 Month Senseonics Chart

1 Month Senseonics Chart

Your Recent History

Delayed Upgrade Clock